| Expression pattern: |
DN |
| Associated gene: |
EIF4A3 |
| Associated microRNA: |
- |
| Biological function: |
Inhibits tumor cell proliferation, migration, invasion, stemness, and metastasis; promotes apoptosis; enhances sensitivity to gemcitabine. |
| Molecular mechanism: |
circPCSK6 encodes circPCSK6-167aa; this peptide regulates IkappaBalpha ubiquitination and inhibits NF-kappaB activation; circPCSK6 is negatively regulated by EIF4A3 via binding/splicing control. |
| Biological pathway or process: |
NF-kappaB (inhibits); proliferation (inhibits); apoptosis (promotes); migration (inhibits); invasion (inhibits); metastasis (inhibits); stemness (inhibits); drug resistance (inhibits) |
| Detected method: |
Q
|
| Validation methods: |
Bioinformatics Analysis; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; Clinical Sample Validation; EdU Staining; Transwell Assay; TUNEL; Western Blot; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Transfection; RIP (RNA Immunoprecipitation); ROC Analysis; Survival Analysis |
| Clinical significance: |
Lower circPCSK6 expression is correlated with unfavorable patient outcomes and adverse prognosis in ICC. |
| Description: |
circPCSK6 (hsa_circ_0037100), derived from the PCSK6 gene, is down-regulated in intrahepatic cholangiocarcinoma and acts as a tumor suppressor. It exerts major effects via its encoded peptide circPCSK6-167aa, which inhibits NF-kappaB signaling by stabilizing IkappaBalpha through reduced ubiquitination, and its expression is negatively regulated by the RBP EIF4A3. |
| Confidence score: |
0.8671 |